Ogsiveo Shortage Update: What Patients Need to Know in 2026

If you've been searching for news about an Ogsiveo shortage, here's the most important thing to know upfront: as of 2026, Ogsiveo (nirogacestat) is not listed on the FDA Drug Shortage Database. The drug is commercially available in the United States through specialty pharmacies. However, "available" and "easy to access" are two very different things for a rare-disease specialty medication.

This update covers the current state of Ogsiveo availability, the formulation changes that occurred in 2025, the real-world access challenges patients are facing, and practical steps to protect your treatment continuity.

Is Ogsiveo in a Shortage Right Now?

No. Ogsiveo is not listed on the FDA's official shortage database as of 2026. SpringWorks Therapeutics (now a subsidiary of Merck KGaA since July 2025) continues to manufacture and supply nirogacestat in the United States through its specialty pharmacy network.

That said, patients regularly report delays in access — and those delays can feel just as disruptive as a true shortage. The barriers are different in nature but similar in impact.

The 50 mg Tablet Discontinuation: What Changed in 2025

The most significant Ogsiveo-related access event of the past two years was not a shortage but a formulation change. As of January 1, 2025, the 50 mg tablet of Ogsiveo was discontinued. SpringWorks Therapeutics replaced it with new 100 mg and 150 mg tablet strengths in blister pack packaging.

The recommended full dose of Ogsiveo is 150 mg twice daily. The new 150 mg tablet simplifies this regimen by replacing the previous three-tablet approach (3 x 50 mg). However, for patients on reduced doses — for example, 100 mg twice daily due to side effect management — the new 100 mg tablet provides a convenient single-tablet alternative.

Patients who were previously stabilized on the 50 mg tablet needed to transition to the new formulations. While this change was ultimately designed to improve patient convenience, it created short-term confusion for some patients and pharmacies in early 2025. The Desmoid Tumor Research Foundation (DTRF) advised patients to contact their physician, pharmacist, or SpringWorks Medical Information team with questions.

Why Do Patients Experience Access Problems If There's No Shortage?

Several structural factors create access delays even when Ogsiveo supply is technically adequate:

Insurance prior authorization delays: Most insurance plans require prior authorization for Ogsiveo, which can take days to weeks to process.

Specialty pharmacy routing restrictions: Your insurance plan designates which specialty pharmacy you can use, and that pharmacy must be confirmed to have stock.

Rare disease unfamiliarity: Because desmoid tumors are rare, some pharmacists and even some insurance case managers are unfamiliar with Ogsiveo, which can slow processing.

High cost and insurer scrutiny: At a list price of approximately $25,000–$30,000 per month, Ogsiveo draws significant scrutiny from payers, sometimes leading to initial denials and appeal processes.

How to Protect Your Treatment Continuity

Here are the most effective steps you can take to protect your access to Ogsiveo:

Enroll in SpringWorks CareConnections. Call 1-844-CARES-55. Their nurse advocates can manage your insurance authorization and alert you to potential gaps.

Request refills early. Initiate refill requests at least 7–10 days before your current supply runs out. Specialty pharmacy processing is not instantaneous.

Know your bridge program options. If you're between insurance coverage periods or waiting on a PA decision, the Quick Start or Gap Coverage programs can provide medication to fill the gap.

Use medfinder to verify pharmacy availability. medfinder is a paid service that calls pharmacies to confirm Ogsiveo availability, helping you quickly identify which specialty pharmacies near you have the drug in stock.

What to Expect Going Forward

Ogsiveo's commercial trajectory is strong — projected revenue for 2026 exceeds $400 million. SpringWorks is investing significantly in supporting patients' access to the drug. No supply constraints or manufacturing disruptions have been reported. The best way to stay protected is to be proactive with your specialty pharmacy and support program enrollment. If your specialty pharmacy ever delays your prescription, see our guide on how to find Ogsiveo in stock near you or learn about alternatives to Ogsiveo if you need a bridge plan.